Chemogenetics-a transformational and translational platform

JAMA Neurology

Volumn 72, Issue 11, 2015, Pages 1361-1366

  English, Justin G ^a   Roth, Bryan L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CLOZAPINE; DESIGNER RECEPTOR EXCLUSIVELY ACTIVATED BY DESIGNER DRUG; DYNORPHIN; ENKEPHALIN; G PROTEIN COUPLED RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; LISURIDE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; PARVOVIRUS VECTOR; RECOMBINANT PROTEIN; SALVINORIN A; SYNAPSIN; UNCLASSIFIED DRUG;

ARTICLE; BIOENGINEERING; BIOTECHNOLOGY; CELL FUNCTION; CONNECTOME; DRUG DELIVERY SYSTEM; GLIA CELL; HUMAN; LEARNING; MEMORY; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEIZURE; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DRUG DESIGN; DRUG EFFECTS; GENETICS; GLIA; METABOLISM; NERVOUS SYSTEM DISEASES; PROCEDURES; PROTEIN ENGINEERING; TRANSLATIONAL RESEARCH;

ANIMALS; BRAIN; DRUG DESIGN; HUMANS; NERVOUS SYSTEM DISEASES; NEUROGLIA; NEURONS; PROTEIN ENGINEERING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84946781241     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.1921     Document Type: Article

References (72)

1. World Health Organization. Neurological disorders: public health challenges. http://www.who.int/mental-health/neurology/neurodiso/en/. Accessed May 31, 2015.
2. Optogenetics: controlling the brain with light [extended version]. http://www.scientificamerican.com/article/optogenetics-controlling/. Accessed May 31, 2015.
3. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A. 2007;104(12):5163-5168.
4. Sternson SM, Roth BL. Chemogenetic tools to interrogate brain functions. Annu Rev Neurosci. 2014;37(1):387-407.
5. Urban DJ, Roth BL. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol. 2015;55(1):399-417.
6. Dell'Anno MT, Caiazzo M, Leo D, et al. Remote control of induced dopaminergic neurons in parkinsonian rats. J Clin Invest. 2014;124(7):3215-3229.
7. Fortress AM, Hamlett ED, Vazey EM, et al. Designer receptors enhance memory in a mouse model of Down syndrome. J Neurosci. 2015;35(4):1343-1353.
8. Kätzel D, Nicholson E, Schorge S, Walker MC, Kullmann DM. Chemical-genetic attenuation of focal neocortical seizures. Nat Commun. 2014;5:3847.
9. Krook-Magnuson E, Soltesz I. Beyond the hammer and the scalpel: selective circuit control for the epilepsies. Nat Neurosci. 2015;18(3):331-338.
10. Penagarikano O, Lazaro MT, Lu X-H, et al. Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism. Sci Transl Med. 2015;7(271):271ra8.
11. Ferguson SM, Neumaier JF. Using DREADDs to investigate addiction behaviors. Curr Opin Behav Sci. 2015;2:69-72.
12. Pleil KE, Rinker JA, Lowery-Gionta EG, et al. NPY signaling inhibits extended amygdala CRF neurons to suppress binge alcohol drinking. Nat Neurosci. 2015;18(4):545-552.
13. Zhang Z, Ferretti V, Guntan., et al. Neuronal ensembles sufficient for recovery sleep and the sedative actions of α2 adrenergic agonists. Nat Neurosci. 2015;18(4):553-561.
14. Unger EK, Burke KJ Jr, Yang CF, Bender KJ, Fuller PM, Shah NM. Medial amygdalar aromatase neurons regulate aggression in both sexes. Cell Rep. 2015;10(4):453-462.
15. Brust RD, Corcoran AE, Richerson GB, Nattie E, Dymecki SM. Functional and developmental identification of a molecular subtype of brain serotonergic neuron specialized to regulate breathing dynamics. Cell Rep. 2014;9(6):2152-2165.
16. Koch M, Varela L, Kim JG, et al. Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature. 2015;519(7541):45-50.
17. Stachniak TJ, Ghosh A, Sternson SM. Chemogenetic synaptic silencing of neural circuits localizes a hypothalamus-midbrain pathway for feeding behavior. Neuron. 2014;82(4):797-808.
18. Vardy E, Robinson JE, Li C, et al. A new DREADD facilitates the multiplexed chemogenetic interrogation of behavior. Neuron. 2015;86(4):936-946.
19. Hsiang H-L, Epp JR, van den Oever MC, et al. Manipulating a "cocaine engram" inmice. J Neurosci. 2014;34(42):14115-14127.
20. Yau JO-Y, McNally GP. Pharmacogenetic excitation of dorsomedial prefrontal cortex restores fear prediction error. J Neurosci. 2015;35(1):74-83.
21. Garner AR, Rowland DC, Hwang SY, et al. Generation of a synthetic memory trace. Science. 2012;335(6075):1513-1516.
22. Nagai Y, Kikuchi E, Lerchner W, et al. In vivo PET imaging of the behaviorally active designer receptor in macaque monkeys. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=f232c34d-6626-4ebe-a852-085554583cdc&cKey=2f80b0d9-aecb-4b9a -970f-3d90a5eb1b59&mKey=%7b54C85D94-6D69-4B09-AFAA-502C0E680CA7%7d. Accessed May 1, 2015.
23. Lerchner W, Eldridge MAG, Saunders RC, et al. Reversible DREADD inactivation of less than 10% of orbitofrontal cortex neurons in interconnection with rhinal cortex is sufficient to disrupt cue discrimination in monkeys. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=f232c34d-6626-4ebe-a852-085554583cdc&cKey=b2968720-75b6-4547-8143-bd1fe599d723&mKey=54c85d94-6d69-4b09-afaa-502c0e680ca7. Accessed August 26, 2015.
24. Eldridge MA, Lerchner W, Minamimoto T, Saunders RC, Richmond BJ. Reversible DREADD inactivation of orbitofrontal cortex neurons in rhesus monkeys with contralateral rhinal cortex removal disrupts cued reward discrimination, I. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=f232c34d-6626-4ebe-a852-085554583cdc&cKey=a1cf507f-8845-4445-ad0d-ae86fe797b3e&mKey=%7B54C85D94-6D69-4B09-AFAA-502C0E680CA7%7D. Accessed August 26, 2015.
25. Allen JA, Roth BL. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2011;51(1):117-144.
26. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353-359.
27. Besnard J, Ruda GF, Setola V, et al. Automated design of ligands to polypharmacological profiles. Nature. 2012;492(7428):215-220.
28. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356(1):6-9.
29. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT (2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102(23):2836-2841.
30. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175-181.
31. Jann MW, Lam YW, Chang WH. Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Arch Int Pharmacodyn Ther. 1994;328(2):243-250.
32. Alexander GM, Rogan SC, Abbas AI, et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron. 2009;63(1):27-39.
33. Chen X, Choo H, Huang X-P, et al. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs. ACS Chem Neurosci. 2015;6(3):476-484.
34. Magnus CJ, Lee PH, Atasoy D, Su HH, Looger LL, Sternson SM. Chemical and genetic engineering of selective ion channel-ligand interactions. Science. 2011;333(6047):1292-1296.
35. Hooker JM, Munro TA, Béguin C, et al. Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence. Neuropharmacology. 2009;57(4):386-391.
36. Guettier J-M, Gautam D, Scarselli M, et al. A chemical-genetic approach to study G protein regulation of β cell function in vivo. Proc Natl Acad Sci U S A. 2009;106(45):19197-19202.
37. Nakajima K, Wess J. Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol. 2012;82(4):575-582.
38. Farrell MS, Pei Y, Wan Y, et al. A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology. 2013;38(5):854-862.
39. Zhu H, Pleil KE, Urban DJ, Moy SS, Kash TL, Roth BL. Chemogenetic inactivation of ventral hippocampal glutamatergic neurons disrupts consolidation of contextual fear memory. Neuropsychopharmacology. 2014;39(8):1880-1892.
40. MacAskill AF, Cassel JM, Carter AG. Cocaine exposure reorganizes cell type-and input-specific connectivity in the nucleus accumbens. Nat Neurosci. 2014;17(9):1198-1207.
41. Krashes MJ, Koda S, Ye C, et al. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest. 2011;121(4):1424-1428.
42. Agulhon C, Boyt KM, Xie AX, Friocourt F, Roth BL, McCarthy KD. Modulation of the autonomic nervous system and behaviour by acute glial cell Gq protein-coupled receptor activation in vivo. J Physiol. 2013;591(pt 22):5599-5609.
43. Ferguson SM, Eskenazi D, Ishikawa M, et al. Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci. 2011;14(1):22-24.
44. Vazey EM, Aston-Jones G. Designer receptor manipulations reveal a role of the locus coeruleus noradrenergic system in isoflurane general anesthesia. Proc Natl Acad Sci U S A. 2014;111(10):3859-3864.
45. Lerchner W, Corgiat B, Der Minassian V, Saunders RC, Richmond BJ. Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain. Gene Ther. 2014;21(3):233-241.
46. Yaguchi M, Ohashi Y, Tsubota T, et al. Characterization of the properties of seven promoters in the motor cortex of rats and monkeys after lentiviral vector-mediated gene transfer. Hum Gene Ther Methods. 2013;24(6):333-344.
47. Kim M-S, Pinto SM, Getnet D, et al. A draft map of the human proteome. Nature. 2014;509(7502):575-581.
48. Developmental Transcriptome. Brain Span: atlas of the developing human brain. http://www.brainspan.org/rnaseq/search/index.html. Accessed May 5, 2015.
49. Usoskin D, Furlan A, Islam S, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci. 2015;18(1):145-153.
50. Salegio EA, Samaranch L, Kells AP, Forsayeth J, Bankiewicz K. Guided delivery of adeno-associated viral vectors into the primate brain. Adv Drug Deliv Rev. 2012;64(7):598-604.
51. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012;20(4):699-708.
52. Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther. 2006;13(3):528-537.
53. Gray SJ, Blake BL, Criswell HE, et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther. 2010;18(3):570-578.
54. Sondhi D, Hackett NR, Peterson DA, et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther. 2007;15(3):481-491.
55. Markakis EA, Leranth C, Bober J, et al. Transduction of neural cells in primate brain using adeno-associated virus (AAV) serotypes 2 and 5. Mol Ther. 2006;13(S1):S46-S47.
56. Markakis EA, Vives KP, Bober J, et al. Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther. 2010;18(3):588-593.
57. Asuri P, Bartel MA, Vazin T, Jang J-H, Wong TB, Schaffer DV. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther. 2012;20(2):329-338.
58. Dalkara D, Byrne LC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5(189):189ra76.
59. Hordeaux J, Dubreil L, Deniaud J, et al. Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats. Gene Ther. 2015;22(4):316-324.
60. Carter ME, Soden ME, Zweifel LS, Palmiter RD. Genetic identification of a neural circuit that suppresses appetite. Nature. 2013;503(7474):111-114.
61. Bru T, Salinas S, Kremer EJ. An update on canine adenovirus type 2 and its vectors. Viruses. 2010;2(9):2134-2153.
62. Schnütgen F, Doerflinger N, Calléja C, Wendling O, Chambon P, Ghyselinck NB. A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse. Nat Biotechnol. 2003;21(5):562-565.
63. Atasoy D, Aponte Y, Su HH, Sternson SM. A FLEX switch targets channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping. J Neurosci. 2008;28(28):7025-7030.
64. Kremer EJ, Boutin S, Chillon M, Danos O. Canine adenovirus vectors: an alternative for adenovirus mediated gene transfer. J Virol. 2000;74(1):505-512.
65. Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol. 2005;79(15):9933-9944.
66. Mangraviti A, Tzeng SY, Kozielski KL, et al. Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. ACS Nano. 2015;9(2):1236-1249.
67. Yu C, Liu Y, Ma T, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2015;16(2):142-147.
68. Doze VA, Perez DM. G-protein-coupled receptors in adult neurogenesis. Pharmacol Rev. 2012;64(3):645-675.
69. Janson C, McPhee S, Bilaniuk L, et al. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther. 2002;13(11):1391-1412.
70. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007;369(9579):2097-2105.
71. Le Witt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10(4):309-319.
72. Watakabe A, Ohtsuka M, Kinoshita M, et al. Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res. 2015;93:144-157.